A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors (NCT07085091)
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants With Advanced or Metastatic Select Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
Who can join: Review the eligibility criteria below.
Location: ALX Center 7 — Tampa, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- ALX Center 7 — Tampa, Florida
- ALX Center 8 — Farmington Hills, Michigan
- ALX Center 3 — Grand Rapids, Michigan
- ALX Center 6 — Portland, Oregon
- ALX Center 5 — Houston, Texas
- ALX Center 4 — West Valley City, Utah
- ALX Center 2 — Fairfax, Virginia
- ALX Center 1 — Spokane, Washington
📞 Contact the Study Coordinator
Phone: (650) 466-7125
Email: info@alxoncology.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in NSCLC (Advanced Non-small Cell Lung Cancer)
- Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy — Port Saint Lucie, Florida
- A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations — Phoenix, Arizona
Explore by condition: All NSCLC (Advanced Non-small Cell Lung Cancer) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.